Merck reported its Keytruda PD-1 drug was approved in China for first-line use in patients with metastatic nonsquamous non-small cell lung cancer (NSCLC), a potentially blockbuster indication. In a global clinical trial, Keytruda reduced deaths by 50% in lung cancer patients. Previously, Keytruda was approved in China as a second-line treatment for metastatic melanoma, a much smaller market. Opdivo, the Bristol-Myers Squibb PD-1 treatment, was approved last year in China as a second-line treatment for NSCLC. More details....
Stock Symbol: (NYSE: MRK)
Share this with colleagues:
Original Article: China Approves Merck's Keytruda, a PD-1 Drug, for First Line NSCLC